UNASYN

Compare UNASYN  to:
Compare
Compare

Generic Name for UNASYN

Ampicillin sodium 1g, sulbactam sodium 0.5g (1.5g vial); or ampicillin sodium 2g, sulbactam sodium 1g (3g vial); IM or IV inj; sodium content 5mEq/g of ampicillin.

Legal Classification:

Rx

Pharmacological Class for UNASYN

Broad-spectrum penicillin + β-lactamase inhibitor.

Manufacturer of UNASYN

Pfizer Labs

Indications for UNASYN

Susceptible skin and skin structure, intraabdominal, gynecologic infections.

Adult dose for UNASYN

Dose is given as ampicillin + sulbactam. Normal renal function (CrCl ≥30mL/min): 1.5–3g IM or IV every 6 hours; CrCl 15–29mL/min: 1.5–3g every 12 hrs; CrCl 5–14mL/min: 1.5–3g every 24 hrs.

Children's dosing for UNASYN

Intraabdominal infections: not recommended. Dose is given as ampicillin + sulbactam. <1yr: not recommended. ≥1yr (<40kg): 300mg/kg per day IV in equally divided doses every 6 hrs; usual max 14 days. ≥40kg: as adult.

Precautions for UNASYN

Cephalosporin, imipenem, other allergy or mononucleosis: not recommended. Pregnancy (Cat.B). Nursing mothers.

Interactions for UNASYN

Potentiated by probenecid. Increased incidence of rash with allopurinol. May cause false (+) Clinitest, Benedict's or Fehling's soln.

Adverse Reactions for UNASYN

Inj site reactions, diarrhea, rash, blood dyscrasias, anaphylaxis, elevated liver enzymes.

How is UNASYN supplied?

Vials (1.5g, 3g)—1

Related Disease:

Infections, bacterial~systemic antiinfectives

Related Resources

Cayston inhaled antibiotic approved for cystic fibrosis

February 23, 2010

The FDA has approved Cayston (aztreonam for inhalation solution, from Gilead Sciences) as a treatment to improve respiratory symptoms in cystic fibrosis (CF) patients with Pseudomonas aeruginosa.

Phase 3 study of fidaxomicin for clostridium difficile infection (CDI)

February 05, 2010

Optimer Pharmaceuticals announced positive top-line results from the second of two Phase 3 trials evaluating the safety and efficacy of fidaxomicin (OPT-80) in patients with Clostridium difficile Infection (CDI).

Exel/Exelint infusion set needles recalled

January 26, 2010

FDA notified healthcare professionals of a Class I recall of Exel/Exelint Huber needles, Exel/Exelint Huber Infusion Sets, and Exel/Exelint "Securetouch+" Safety Huber Infusion Sets due to 'coring,' the cutting or dislodging of silicone cores or slivers from the ports into which they are inserted).

Phase 2 study of Arikace for treatment of pseudomonas lung infections

October 19, 2009

Transave reported additional positive clinical trial results on its lead investigational drug, Arikace (liposomal amikacin for inhalation), an antibiotic to treat chronic lung infections.

Vibativ approved for complicated skin and skin structure infections

September 18, 2009

The FDA has approved Vibativ (telavancin, from Theravance and Astellas), a bactericidal, once-daily injectable lipoglycopeptide antibiotic.